GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (TSXV:ACST) » Definitions » ROA %

Acasti Pharma (TSXV:ACST) ROA % : -12.34% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Acasti Pharma's annualized Net Income for the quarter that ended in Dec. 2023 was C$-12.83 Mil. Acasti Pharma's average Total Assets over the quarter that ended in Dec. 2023 was C$104.02 Mil. Therefore, Acasti Pharma's annualized ROA % for the quarter that ended in Dec. 2023 was -12.34%.

The historical rank and industry rank for Acasti Pharma's ROA % or its related term are showing as below:

TSXV:ACST' s ROA % Range Over the Past 10 Years
Min: -144   Med: -43.49   Max: -3.74
Current: -45.79

During the past 13 years, Acasti Pharma's highest ROA % was -3.74%. The lowest was -144.00%. And the median was -43.49%.

TSXV:ACST's ROA % is ranked worse than
58.74% of 1551 companies
in the Biotechnology industry
Industry Median: -34.84 vs TSXV:ACST: -45.79

Acasti Pharma ROA % Historical Data

The historical data trend for Acasti Pharma's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma ROA % Chart

Acasti Pharma Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -145.55 -87.68 -44.80 -10.30 -42.83

Acasti Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.21 -119.28 -20.83 -17.47 -12.34

Competitive Comparison of Acasti Pharma's ROA %

For the Biotechnology subindustry, Acasti Pharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acasti Pharma's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acasti Pharma's ROA % distribution charts can be found below:

* The bar in red indicates where Acasti Pharma's ROA % falls into.



Acasti Pharma ROA % Calculation

Acasti Pharma's annualized ROA % for the fiscal year that ended in Mar. 2023 is calculated as:

ROA %=Net Income (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=-58.056/( (162.833+108.264)/ 2 )
=-58.056/135.5485
=-42.83 %

Acasti Pharma's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-12.832/( (105.826+102.21)/ 2 )
=-12.832/104.018
=-12.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Acasti Pharma  (TSXV:ACST) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-12.832/104.018
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-12.832 / 0)*(0 / 104.018)
=Net Margin %*Asset Turnover
=N/A %*0
=-12.34 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Acasti Pharma ROA % Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acasti Pharma (TSXV:ACST) Business Description

Traded in Other Exchanges
Address
3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Executives
Donald John Olds Director